7月9日，快而精医药盘中上涨12.83%，报42.875美元/股，成交额2.88亿美元。
消息面上，据彭博报道，私募股权巨头EQT、Advent及KKR已对快而精医药表达初步收购兴趣。事实上，早在今年1月，市场即传出快而精医药正考虑包括出售在内的多种战略选项，当时股价已因此消息一度跳涨逾10%。此次多家头部PE机构同时入场竞标的消息进一步强化了交易落地预期，推动股价大幅走高。
快而精医药是全球领先的"样本到洞察"解决方案提供商，在分子诊断及生命科学领域为超过50万客户提供服务，产品覆盖100多个国家。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.